[Efficacy and safety of treatment with ampasse: the results of a randomized, double-blind, placebo-controlled trial in patients with chronic cerebrovascular disorders].

A A Skoromets S V Kotov P B Voronkov V V Popova T G Zubkova A V Kiselev

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2021)

Ampasse has a positive effect on cognitive functions and QOL, does not increase the frequency of adverse events in patients with CCVD compared to placebo, does not cause significant side effects, and is well tolerated by patients.

Keyphrases

double blind
end stage renal disease
placebo controlled
clinical trial
ejection fraction
newly diagnosed
peritoneal dialysis
randomized controlled trial
phase ii
open label